Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients
NCT ID: NCT01178684
Last Updated: 2014-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
113 participants
OBSERVATIONAL
2010-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
NCT00225082
Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue
NCT00647946
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
NCT00028314
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
NCT01813292
Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.
NCT00540111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis
1. HIV-positive patients who have been on long-term d4T treatment with symptomatic peripheral neuropathy will have less ENFD, increased lipoatrophy, and altered mitochondrial function than those on long-term d4T treatment with asymptomatic peripheral neuropathy and those on long-term d4T treatment without peripheral neuropathy.
2. HIV-negative patients without peripheral neuropathy will have more ENFD, no lipoatrophy, and better mitochondrial function than HIV-positive patients.
The SEARCH 003 study will assess the extent of deterioration in ENFD induced by short-term (from entry to 24 weeks) d4T use and the degree of improvement following discontinuation of d4T (from week 24 to 72). However the range of changes in ENFD and in other mitochondrial parameters induced by d4T-based therapy in not known, globally or specifically in the Thai population.
This is a cross-sectional study that will enroll 25 HIV-positive subjects on long-term d4T treatment with symptomatic peripheral neuropathy, 25 HIV-positive subjects on long-term d4T treatment without peripheral neuropathy, 50 HIV-negative subjects without peripheral neuropathy and 25 HIV-positive subjects on long-term d4T treatment with asymptomatic peripheral neuropathy for a one-time assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: HIV-pos on d4T with neuropathy
No interventions assigned to this group
2: HIV-pos on d4T without neuropathy
No interventions assigned to this group
3: HIV-neg without peripheral neuropathy
No interventions assigned to this group
4 HIV-pos on d4T with asymtomatic neuropathy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years old
* Has Thai national identification card
* Subject on d4T treatment with symptoms of neuropathy which developed after start of d4T therapy
* Evidence of symptomatic persistent symptoms of pain, tingling or numbness of lower extremities AND bilateral lower extremity neuropathy on exam at entry.
* Subject understands the study and is able to sign informed consent
* HIV RNA by PCR \< 50 copies/mL
Exclusion Criteria
* History of allergy to any anesthetic medications
* Pregnancy
Group 2 subjects will meet the same criteria described above for group 1 subjects, but will NOT have symptoms OR signs of neuropathy.
Group 3 subjects will meet the same criteria described above for group 1 subjects, but will NOT have symptoms OR signs of neuropathy and will have documented
Group 4 subjects will meet the same criteria described above for group 1 subject, but will have evidence of symptomatic persistent symptoms of pain, tingling or numbness of lower extremities.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Hawaii
OTHER
SEARCH Research Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assoc.Prof.Jintanat Ananworanich, M.D.
Assoc.Prof. Jintanat Ananworanich, MD,PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jintanat Ananworanich, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
SEARCH Research Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thai Red Cross AIDS Research Centre
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEARCH 014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.